14 March 2022 - Incyte announced today that the U.S. FDA has extended the review period for the supplemental new ...
9 March 2022 - The FDA plans to hold an advisory committee meeting. ...
4 March 2022 - Australian patients will have improved access to clinical trials due to reforms to be introduced by ...
3 March 2022 - FDA sets updated PDUFA goal date of June 25, 2022. ...
28 February 2022 - AbbVie today announced that the U.S. FDA has extended its review period for Skyrizi (risankizumab-rzaa) for ...
24 February 2022 - MannKind Corporation was informed that the U.S. FDA issued an information request to United Therapeutics Corporation ...
24 February 2022 - Major amendment to Tyvaso DPI new drug application pushes FDA decision date to May 2022. ...
24 February 2022 - FDA sets updated PDUFA goal date of 16 June 2022. ...
21 February 2022 - University of Illinois Chicago researchers studied 135 products that received U.S. FDA approval through orphan drug and ...
10 February 2022 - Following consultation with members – and heeding the concerns of the Consumers Health Forum and patient ...
8 February 2022 - The consultation period on the draft NMP was due to close on Wednesday 16 February 2022. ...
4 February 2022 - Medicines Australia is today calling for the new National Medicines Policy to be pushed back until ...
2 February 2022 - Significant clarification of the life-changing Early Access to Medicines Scheme to be introduced into law. ...
25 January 2022 - The European Medicines Agency wants to get a better understanding of drug companies’ commercial intentions and why. ...
28 January 2022 - Medicines Australia recommends the Australian Government delivers a plan to shorten the time that patients wait ...